


Revizinone

Cat. No.:	HY-100615		
CAS No.:	133718-29-3		
Molecular Formula:	C ₂₆ H ₂₉ N ₅ O ₃		
Molecular Weight:	459.54		
Target:	Phosphodiesterase (PDE)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 4.6 mg/mL (10.01 mM)
 * "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1761 mL	10.8804 mL	21.7609 mL
	5 mM	0.4352 mL	2.1761 mL	4.3522 mL
	10 mM	0.2176 mL	1.0880 mL	2.1761 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Revizinone is a novel selective phosphodiesterase (PDE) inhibitor with IC₅₀ values on this enzyme to 0.036 microM. target: phosphodiesterase (PDE)[3]; IC₅₀: 0.036 microM; [3] In vivo: The administration of Revizinone improved the haemodynamic profile with an increase in cardiac output, a decrease in systemic vascular resistance and a stable heart rate and mean arterial blood pressure. [1] With regard to reconstitution of contractility and cardiac function Revizinone (E-isomer) was 10 fold more potent than R 79595 and nearly 100 fold more potent than R 80123 (Z-isomer). [2] Revizinone significantly increased global LV function and systolic wall thickening in ischemic areas at doses greater than or equal to 0.16 mg/kg i.v. [4]

REFERENCES

- [1]. Herregods L et al. Haemodynamic effects of R 80122 immediately after cardiopulmonary bypass; preliminary results. *Anaesthesia*. 1994 Aug;49(8):719-22.
- [2]. Schneider J et al. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotoxic agents with highly

selective phosphodiesterase III inhibitory properties. Naunyn Schmiedebergs Arch Pharmacol

[3]. de Cheffoy de Courcelles D et al. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14.

[4]. Vandeplassche GM et al. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. J Cardiovasc Pharmacol. 1992 May;19(5):714-22

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA